Fingolimod Capsules
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D2-26-R-0007
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents3
The Defense Logistics Agency (DLA) Troop Support, operating under the Department of Defense, has issued a solicitation (SPE2D2-26-R-0007) for the supply of Fingolimod Capsules. This procurement is classified under NAICS Code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and carries the Product Service Code 6505, indicating a focus on drugs and biologicals.
The primary objective of this solicitation is to secure a reliable source of Fingolimod Capsules, a pharmaceutical product used in the treatment of certain medical conditions. The scope of the contract is expected to encompass the manufacturing and timely delivery of these capsules, ensuring that the DLA Troop Support can meet the ongoing needs of its constituents. The intended outcome is to maintain a consistent supply chain for this critical medication, supporting the health and readiness of personnel served by the agency.
Key requirements for prospective contractors include compliance with all applicable pharmaceutical manufacturing standards and regulations, as dictated by the NAICS classification. Offerors should be prepared to demonstrate their capacity for large-scale production, quality assurance, and distribution of Fingolimod Capsules. The solicitation may include specific technical, packaging, and delivery requirements, which are detailed in the attached documents available via the SAM.gov opportunity link.
The contracting entity is DLA Troop Support, a federal office within the Defense Logistics Agency. The primary point of contact for this solicitation is Henry Shelly, who can be reached at [email protected] or 267-453-0756. A secondary contact is Jason Wray, available at [email protected] or 445-737-6304. Interested parties are encouraged to direct all inquiries and submissions to these contacts.
The solicitation was posted on July 22, 2026, and remains active, with a response deadline set for August 6, 2026. Contractors should review the three attachments provided on the SAM.gov opportunity page for comprehensive details regarding submission requirements, evaluation criteria, and contract terms. The procurement type is a formal solicitation; however, no information regarding set-aside requirements or special considerations has been provided in the notice.
This opportunity is well-suited for established pharmaceutical manufacturers with proven capabilities in producing and supplying prescription medications to federal agencies. Contractors should ensure their operations align with the constant requirements of quality, regulatory compliance, and reliable delivery throughout the contract lifecycle. For further information and to access solicitation documents, visit the official SAM.gov listing at https://sam.gov/opp/7d81c822c7c445a09efe4079813d2d4b/view.